Hørlyck A

ORCID: 0000-0003-4624-6973 · 1 paper in corpus · active 2021
2021
National, clinical cohort study of late effects among survivors of acute lymphoblastic leukaemia: the ALL-STAR study protocol.
BMJ open ·doi:10.1136/bmjopen-2020-045543

IntroductionMore than 90% of patients diagnosed with childhood acute lymphoblastic leukaemia (ALL) today will survive. However, half of the survivors are expected to experience therapy-related chronic or late occurring adverse effects, redu…